OT-404, multi-targeted anti-cancer agent affecting tumor proliferation, chemo-resistance, and angiogenesis
dc.contributor.author | Rebbaa, Abdelhadi | |
dc.contributor.author | Patil, Ghanshyam | |
dc.contributor.author | Sudha, Thangirala | |
dc.contributor.author | Mousa, Shaker A. | |
dc.contributor.buuauthor | Yalçın, Murat | |
dc.contributor.department | Uludağ Üniversitesi/Veterinerlik Fakültesi/Veteriner Hekimliği Temel Bilimler Bölümü. | tr_TR |
dc.contributor.orcid | 0000-0002-5600-8162 | tr_TR |
dc.contributor.researcherid | AAG-6956-2021 | tr_TR |
dc.contributor.scopusid | 57192959734 | tr_TR |
dc.date.accessioned | 2023-05-26T07:58:17Z | |
dc.date.available | 2023-05-26T07:58:17Z | |
dc.date.issued | 2013-05 | |
dc.description.abstract | There is a need for a comprehensive anti-cancer strategy that simultaneously targets abnormal proliferation, angiogenesis rates, and development of chemotherapy resistance. We have identified a small molecule, OT-404, that effectively inhibited proliferation and angiogenesis of either chemo-sensitive or resistant human cancer cells and enhanced cancer cell sensitivity to different chemotherapy. In vivo studies of human tumor xenografts in nude mice showed that OT-404, used alone or encapsulated into nanoparticles, inhibited the growth of doxorubicin-resistant breast cancer MCF-7 by more than 80%, and by 95% when combined with doxorubicin. These findings provide evidence for the potential of OT-404 in cancer management. | en_US |
dc.description.sponsorship | Othera Pharmaceuticals | en_US |
dc.identifier.citation | Rebbaa, A. vd. (2013). “OT-404, multi-targeted anti-cancer agent affecting tumor proliferation, chemo-resistance, and angiogenesis”. Cancer Letters, 332(1), 55-62. | en_US |
dc.identifier.endpage | 62 | tr_TR |
dc.identifier.issn | 0304-3835 | |
dc.identifier.issn | 1872-7980 | |
dc.identifier.issue | 1 | tr_TR |
dc.identifier.pubmed | 23348692 | tr_TR |
dc.identifier.scopus | 2-s2.0-84875255335 | tr_TR |
dc.identifier.startpage | 55 | tr_TR |
dc.identifier.uri | https://doi.org/10.1016/j.canlet.2013.01.016 | |
dc.identifier.uri | http://hdl.handle.net/11452/32804 | |
dc.identifier.volume | 332 | tr_TR |
dc.identifier.wos | 000316775500008 | tr_TR |
dc.indexed.pubmed | PubMed | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.wos | SCIE | en_US |
dc.language.iso | en | en_US |
dc.publisher | Elsevier | en_US |
dc.relation.collaboration | Yurtdışı | tr_TR |
dc.relation.journal | Cancer Letters | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Oncology | en_US |
dc.subject | Angiogenesis | en_US |
dc.subject | Chemo-resistance | en_US |
dc.subject | Nanoparticles | en_US |
dc.subject | OT-404 | en_US |
dc.subject | Hormone-releasing-hormone | en_US |
dc.subject | Endothelial growth-factor | en_US |
dc.subject | Thyroid-hormone | en_US |
dc.subject | Prongiogenic action | en_US |
dc.subject | Kinase inhibitor | en_US |
dc.subject | Tyrosine kinase | en_US |
dc.subject | Down-regülation | en_US |
dc.subject | Cancer-therapy | en_US |
dc.subject | Phase-II | en_US |
dc.subject | In-vivo | en_US |
dc.subject | Mus musculus | en_US |
dc.subject.emtree | Antineoplastic agent | en_US |
dc.subject.emtree | Doxorubicin | en_US |
dc.subject.emtree | Etoposide | en_US |
dc.subject.emtree | Fibroblast growth factor 2 | en_US |
dc.subject.emtree | Nanoparticle | en_US |
dc.subject.emtree | Ot 404 | en_US |
dc.subject.emtree | Unclassified drug | en_US |
dc.subject.emtree | Animal cell | en_US |
dc.subject.emtree | Animal experiment | en_US |
dc.subject.emtree | Antineoplastic activity | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Breast cancer | en_US |
dc.subject.emtree | Cancer cell | en_US |
dc.subject.emtree | Cancer growth | en_US |
dc.subject.emtree | Carcinogenesis | en_US |
dc.subject.emtree | Controlled study | en_US |
dc.subject.emtree | Drug efficacy | en_US |
dc.subject.emtree | Drug mechanism | en_US |
dc.subject.emtree | Drug targeting | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Human cell | en_US |
dc.subject.emtree | In vivo study | en_US |
dc.subject.emtree | Male | en_US |
dc.subject.emtree | Mouse | en_US |
dc.subject.emtree | Nonhuman | en_US |
dc.subject.emtree | Priority journal | en_US |
dc.subject.emtree | Tumor growth | en_US |
dc.subject.emtree | Tumor volume | en_US |
dc.subject.emtree | Tumor xenograft | en_US |
dc.subject.mesh | Angiogenesis inhibitors | en_US |
dc.subject.mesh | Animals | en_US |
dc.subject.mesh | Antineoplastic combined chemotherapy protocols | en_US |
dc.subject.mesh | Breast neoplasms | en_US |
dc.subject.mesh | Cell proliferation | en_US |
dc.subject.mesh | Chemistry, pharmaceutical | en_US |
dc.subject.mesh | Dose-response relationship, drug | en_US |
dc.subject.mesh | Doxorubicin | en_US |
dc.subject.mesh | Drug resistance, neoplasm | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | MCF-7 cells | en_US |
dc.subject.mesh | Mice | en_US |
dc.subject.mesh | Mice, inbred C57BL | en_US |
dc.subject.mesh | Mice, nude | en_US |
dc.subject.mesh | Nanocapsules | en_US |
dc.subject.mesh | Neovascularization, physiologic | en_US |
dc.subject.mesh | Time factors | en_US |
dc.subject.mesh | Tumor burden | en_US |
dc.subject.mesh | U937 cells | en_US |
dc.subject.mesh | Xenograft model antitumor assays | en_US |
dc.subject.scopus | Hsp90 Inhibitor; Ganetespib; Tanespimycin | en_US |
dc.subject.wos | Oncology | en_US |
dc.title | OT-404, multi-targeted anti-cancer agent affecting tumor proliferation, chemo-resistance, and angiogenesis | en_US |
dc.type | Article | |
dc.wos.quartile | Q1 | en_US |
Files
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: